These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 25759016)

  • 1. Seek and destroy: relating cancer drivers to therapies.
    Martinez-Ledesma E; de Groot JF; Verhaak RG
    Cancer Cell; 2015 Mar; 27(3):319-21. PubMed ID: 25759016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities.
    Rubio-Perez C; Tamborero D; Schroeder MP; Antolín AA; Deu-Pons J; Perez-Llamas C; Mestres J; Gonzalez-Perez A; Lopez-Bigas N
    Cancer Cell; 2015 Mar; 27(3):382-96. PubMed ID: 25759023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer drugs: Advancing precision medicine in silico.
    Cully M
    Nat Rev Drug Discov; 2015 May; 14(5):311. PubMed ID: 25907342
    [No Abstract]   [Full Text] [Related]  

  • 4. In silico analysis of tumors identifies cancer treatment strategies.
    Cancer Discov; 2015 May; 5(5):OF16. PubMed ID: 25813349
    [No Abstract]   [Full Text] [Related]  

  • 5. PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data.
    Piñeiro-Yáñez E; Reboiro-Jato M; Gómez-López G; Perales-Patón J; Troulé K; Rodríguez JM; Tejero H; Shimamura T; López-Casas PP; Carretero J; Valencia A; Hidalgo M; Glez-Peña D; Al-Shahrour F
    Genome Med; 2018 May; 10(1):41. PubMed ID: 29848362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolution of computational hemodynamics as a clinical tool in decision making, patient specific treatment and clinical management. Part II.
    Gallo D; Anayiotos A; Morbiducci U
    Ann Biomed Eng; 2015 Jun; 43(6):1273-4. PubMed ID: 25986956
    [No Abstract]   [Full Text] [Related]  

  • 7. Considerations About the Use of Biomarkers in Cancer Clinical Trials.
    Chabner BA
    Clin Pharmacol Ther; 2018 Jan; 103(1):25-27. PubMed ID: 29134628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PATIENT-SPECIFIC DATA FUSION FOR CANCER STRATIFICATION AND PERSONALISED TREATMENT.
    Gligorijević V; Malod-Dognin N; Pržulj N
    Pac Symp Biocomput; 2016; 21():321-32. PubMed ID: 26776197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circular RNAs in cancer: opportunities and challenges in the field.
    Kristensen LS; Hansen TB; Venø MT; Kjems J
    Oncogene; 2018 Feb; 37(5):555-565. PubMed ID: 28991235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current cancer driver variant predictors learn to recognize driver genes instead of functional variants.
    Raimondi D; Passemiers A; Fariselli P; Moreau Y
    BMC Biol; 2021 Jan; 19(1):3. PubMed ID: 33441128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer Precision Medicine: Why More Is More and DNA Is Not Enough.
    Schütte M; Ogilvie LA; Rieke DT; Lange BMH; Yaspo ML; Lehrach H
    Public Health Genomics; 2017; 20(2):70-80. PubMed ID: 28595192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic Mutation Analysis of Human Cancers: Challenges in Clinical Practice.
    Tsongalis GJ; Coleman WB
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S60-S66. PubMed ID: 28921651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ConsensusDriver Improves upon Individual Algorithms for Predicting Driver Alterations in Different Cancer Types and Individual Patients.
    Bertrand D; Drissler S; Chia BK; Koh JY; Li C; Suphavilai C; Tan IB; Nagarajan N
    Cancer Res; 2018 Jan; 78(1):290-301. PubMed ID: 29259006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systems Pharmacology-Based Discovery of Natural Products for Precision Oncology Through Targeting Cancer Mutated Genes.
    Fang J; Cai C; Wang Q; Lin P; Zhao Z; Cheng F
    CPT Pharmacometrics Syst Pharmacol; 2017 Mar; 6(3):177-187. PubMed ID: 28294568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Personalization of Therapy: Molecular Profiling Technologies and Their Application.
    Zeron-Medina J; Ochoa de Olza M; Braña I; Rodon J
    Semin Oncol; 2015 Dec; 42(6):775-87. PubMed ID: 26615125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functionally Assessing Candidate Drivers Advances Precision Cancer Medicine.
    Scott KL; Powers S
    Cancer Cell; 2016 Aug; 30(2):187-189. PubMed ID: 27505666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy in cancer.
    Tsimberidou AM
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical tumor sequencing: opportunities and challenges for precision cancer medicine.
    Damodaran S; Berger MF; Roychowdhury S
    Am Soc Clin Oncol Educ Book; 2015; ():e175-82. PubMed ID: 25993170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
    Tsimberidou AM
    Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations.
    Mularoni L; Sabarinathan R; Deu-Pons J; Gonzalez-Perez A; López-Bigas N
    Genome Biol; 2016 Jun; 17(1):128. PubMed ID: 27311963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.